University of California San Francisco
Give to UCSF
The problem of antibiotic resistance and how research may help keep drugs effective was the topic of this year’s Byers Award Lecture in Basic Science, given by Danica Galonić Fujimori, PhD, on Jan. 31.
UC San Francisco and Pfizer Inc.’s Centers for Therapeutic Innovation have renewed an agreement to identify and develop biologic compounds against both known and novel targets.
Steven Altschuler and Lani Wu are using artificial intelligence to spot and label potential medical uses for biological compounds.
In findings that show the effectiveness of a new strategy for treating multiple sclerosis, researchers are reporting positive results from three large, international, multicenter Phase III clinical trials of the investigational drug ocrelizumab in both relapsing multiple sclerosis and primary progressive multiple sclerosis.
The U.S. Food and Drug Administration has awarded the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation (UCSF-Stanford CERSI) a five-year grant with up to $25 million in funding.
UCSF has ranked as one of the top 20 universities in the world, according to the 2017 Best Global Universities rankings released Tuesday by U.S. News & World Report.
An international team of researchers has developed a new opioid drug candidate that blocks pain without triggering the dangerous side effects of current prescription painkillers.
The first results from a large international study of patients taking metformin, the world’s most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better to the drug than others.
A drug commonly used to treat high blood pressure has been shown to significantly reduce the risk of blocked electrical impulses to the heart and could be an effective treatment for certain types of heart disease known as conduction disease, in which the progression of electrical impulses through the heart is impeded.
